SubsidieMeestersInhibiting resistance to immunotherapy in Oncology by targeting Netrin-1
The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments.
Projectdetails
Introduction
Immune Checkpoint Inhibitors (ICPIs) have recently revolutionized the treatment and management of cancer. Yet, progress recorded and impact on long-term survival affect only a limited fraction of patients, as most of the cancer patients do not or incompletely respond to ICPIs due to primary or secondary resistance to these treatments.
Company Overview
NETRIS Pharma is an innovative biotech company based in Lyon. The company has developed NP137, a humanized monoclonal antibody targeting NETRIN-1, able to drive tumor growth inhibition and alleviate resistance to ICPIs, both impacts already confirmed in preclinical models.
Project Objective
The objective of the IMMUNONET project is to conduct a proof-of-efficacy clinical trial assessing the efficacy of NP137 to alleviate suspected resistance to ICPIs.
Expected Impact
The increased response rate to ICPIs with NP137 would have a major impact on patients having limited treatment options beyond immunotherapies and create significant growth opportunities for NETRIS.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 8.327.233 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 31-12-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- NETRIS PHARMA SASpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer careNectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology. | EIC Accelerator | € 2.499.998 | 2024 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
canceR agnOstic immUnoTherapy predIctioN blood-tEstPamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment. | EIC Accelerator | € 2.500.000 | 2023 | Details |
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
canceR agnOstic immUnoTherapy predIctioN blood-tEst
PamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
REPRESSIT: A novel class of clinical immune checkpoint inhibitorsThe REPRESSIT project aims to develop novel ligand-independent checkpoint therapeutics that reactivate exhausted T and NK cells by inhibiting immune receptor signaling, improving cancer treatment efficacy. | EIC Pathfinder | € 2.896.496 | 2023 | Details |
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune responseThis project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer. | ERC Proof of... | € 150.000 | 2025 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapyThe project aims to develop novel Nanobodies as safe and effective modulators of immune checkpoint complexes for cancer and autoimmune diseases, potentially outperforming current therapies. | ERC Advanced... | € 2.499.674 | 2024 | Details |
Bispecific bi-paratopic antibodies for the treatment of cancerThis project aims to develop novel bispecific antibodies to enhance immune response in NSCLC by targeting dual epitopes, potentially improving treatment outcomes for resistant cancer patients. | ERC Proof of... | € 150.000 | 2025 | Details |
REPRESSIT: A novel class of clinical immune checkpoint inhibitors
The REPRESSIT project aims to develop novel ligand-independent checkpoint therapeutics that reactivate exhausted T and NK cells by inhibiting immune receptor signaling, improving cancer treatment efficacy.
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune response
This project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapy
The project aims to develop novel Nanobodies as safe and effective modulators of immune checkpoint complexes for cancer and autoimmune diseases, potentially outperforming current therapies.
Bispecific bi-paratopic antibodies for the treatment of cancer
This project aims to develop novel bispecific antibodies to enhance immune response in NSCLC by targeting dual epitopes, potentially improving treatment outcomes for resistant cancer patients.